Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
RESEARCH TOOLSreports
Holding ITRM?
Track your performance easily
ITRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $2.50
Previous Close$1.77
Volume815.85K
Average Volume (3M)2.51M
Market Cap
$48.70M
Enterprise Value$47.91M
Total Cash (Recent Filing)$14.50M
Total Debt (Recent Filing)$13.71M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Mar 31, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding27,515,926
10 Day Avg. Volume1,053,718
30 Day Avg. Volume2,505,565
Standard Deviation0.38
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$5.00Price Target Upside176.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Iterum Therapeutics News
PremiumMarket News
3 Penny Stocks to Watch Now, 10/29/24
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe uUTI space has a substantial market opportunity with a large population of women at elevated risk, representing over 40 million prescriptions per year.
Regulatory ApprovalThe FDA approved oral sulopenem, brand name ORLYNVAH, for the treatment of uncomplicated urinary tract infections in adult women with limited or no alternative oral antibiotic treatment.
Unmet Medical NeedSulopenem could be the first treatment for uUTI patients with a history of infections with organisms producing extended-spectrum beta-lactamase, reducing risks and costs by shifting to an oral therapy.
Bears Say
Clinical Trial ResultsPrior P3 trials missed on non-inferiority in cipro-susceptible cases.
Market PerformanceIt has been a long road to get here with the CRL for uUTI weighing on ITRM shares, which was further exacerbated by challenging biotech markets.
Regulatory ConcernsSulopenem's use could be more limited than anticipated due to a more restrictive label given the concerns of antimicrobial resistance against carbapenems.
---
Ownership Overview
8.89% Insiders
0.04% Mutual Funds
7.18% Other Institutional Investors
83.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.81 and its highest was $2.50 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Currently, no data Available
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is Mar 31, 2025 which is in 128 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.065.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -$0.22.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 27,515,926 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went down -4.895%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Among the largest hedge funds holding Iterum Therapeutics Plc’s share is New Leaf Venture Partners, L.L.C.. It holds Iterum Therapeutics Plc’s shares valued at 376K.
---
Iterum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (176.24% Upside)
$5.00 (176.24% Upside)
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 34.0%
Last 30 Days ▲ 34.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
---
ITRM Earnings Call
Q3 2024
0:00 / 0:00
---
ITRM Stock 12 Month Forecast
Average Price Target
$5.00
▲(176.24% Upside)
Technical Analysis
Best Analysts Covering ITRM
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+12.13%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +12.13% per trade.
---